Breaking Finance News

Ardelyx Inc (NASDAQ:ARDX) has been upgraded to Sell in a statement by ValuEngine earlier today.

ValuEngine has upgraded Ardelyx Inc (NASDAQ:ARDX) to Sell in a statement released on 7/6/2017.

Having a price of $5.10, Ardelyx Inc (NASDAQ:ARDX) traded 5.15% higher on the day. With the last close down -45.47% from the two hundred day average, compared with the S&P 500 Index which has increased 0.05% over the same period. Ardelyx Inc has recorded a 50-day average of $5.27 and a two hundred day average of $9.35. Volume of trade was down over the average, with 210,830 shares of ARDX changing hands under the typical 510,064

Performance Chart

Ardelyx Inc (NASDAQ:ARDX)

With a total market value of $0, Ardelyx Inc has with a one year low of $4.05 and a one year high of $16.30 .

A total of 6 analysts have released a report on Ardelyx Inc. Four analysts rating the company a strong buy, two analysts rating the company a buy, zero analysts rating the company a hold, zero analysts rating the company a underperform, and finally zero analysts rating the company a sell with a 12-month price target of $19.50.

More About Ardelyx Inc (NASDAQ:ARDX)

Ardelyx, Inc. is a clinical-stage biopharmaceutical company. The Company's therapeutics focuses on addressing cardiorenal and gastrointestinal (GI) diseases. It operates through the research, development and commercialization of biopharmaceutical products segment. The Company's products line includes cardiorenal portfolio and gastrointestinal portfolio. The Company's cardiorenal portfolio includes two Phase III clinical product candidates, tenapanor in Phase III clinical development for treating hyperphosphatemia in end-stage renal disease (ESRD) patients on dialysis and RDX7675 in Phase III clinical development for treating hyperkalemia in chronic kidney disease (CKD) and heart failure patients. The cardiorenal portfolio includes tenapanor, RDX7675, RDX013 and RDX011. Its gastrointestinal portfolio is led by tenapanor for the treatment of irritable bowel syndrome with constipation (IBS-C). The gastrointestinal portfolio includes tenapanor, RDX8940, RDX011 and RDX023.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *